Presenting at 8:00 am Eastern time on March 14, 2019 JERUSALEM , March 13, 2019 /PRNewswire/ --   Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today announces that the Company's presentation time at Barclays Global Healthcare Conference has been changed as follows.

JERUSALEM , Feb. 28, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today announces that Company management will participate at the following upcoming investment conferences in March.  Cowen 39th Annual Health Care Conference Date: March 11-13, 2019 Company

JERUSALEM , Feb. 27, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today announces financial results for the fourth quarter and year ended December 31, 2018 and provides a corporate update.  Highlights of the fourth quarter 2018 and recent weeks include:

AP-CD/LD met primary endpoint of reducing plasma levodopa variability compared to standard oral CD/LD with statistical significance JERUSALEM , Feb. 19, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today announces the preliminary results from a pharmacokinetic

Pursuing medical cannabinoids for a variety of pain indications JERUSALEM , Jan. 2, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today announces the dosing of the first patient in a Phase 1 pharmacokinetic (PK) study of AP-THC, its proprietary Accordion

Reviews 2018 progress and provides outlook for 2019 JERUSALEM , Dec. 19, 2018 /PRNewswire/ --    Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today announces that Jeffrey A. Meckler , Vice Chairman and Chief Executive Officer of Intec Pharma , has issued a Letter to Shareholders,

Accordion Pill for proprietary compound achieves in-vitro specifications Moving into clinical pharmacokinetic (PK) study in 2019 JERUSALEM , Dec. 6, 2018 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today announces that the Accordion Pill™ developed for a

Completed enrollment in pivotal Phase 3 ACCORDANCE trial; on track for topline data in mid-2019 JERUSALEM , Nov. 9, 2018 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today announces financial results for the three and nine months ended September 30, 2018 and

JERUSALEM , Nov. 6, 2018 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today announces that Company management will participate at the following upcoming investment conferences in November.  H.C. Wainwright 2018 Annual Israel Conference Date: November 11, 2018

On Track to Report Topline Data in Mid-2019 for Potential New Baseline Levodopa Treatment JERUSALEM , Oct. 22, 2018 /PRNewswire/ --  Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today announces the completion of patient enrollment in the Company's pivotal Phase 3 clinical trial